ITGAM and colorectal carcinoma: CRC patients showed significantly higher levels of circulating CD33+CD11b+HLA-DR−/lowCD15+ cells compared with HD (CRC: 75.8 ± 2.8%, HD: 67.1 ± 2.7%; Figure 1B).